PSA Testing Guidelines
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses PSA testing guidelines.
Clinical Pearls
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses PSA testing guidelines.
- Rather than focus on one guideline or another, physicians should focus on a model of informed decision making
- A dichotomy exists between those that treat prostate cancer and those that do not
- PSA testing adds value but also brings a potential for harm
- Following PSA testing, a physician should be open to the concept of surveillance before making a decision
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
FPI-2265 Dosing Commences in Phase 2 AlphaBreak Trial for mCRPC
May 10th 2024The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.
Read More
